Elizabeth Pham

University of California, Santa Cruz — United States

Medicine · Health Sciences

15h-index1.9kcitations72works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(13), Advanced Biosensing Techniques and Applications(11), Cancer, Hypoxia, and Metabolism(8), Cancer Immunotherapy and Biomarkers(7), Nanoplatforms for cancer theranostics(7)

Publications72 total

CURE-ating the substrate scope and functional residues of nonheme iron(II) α-ketoglutarate dependent hydroxylase BesE
2025Open Access
1972P Modeling of pemetrexed maintenance de-escalation strategies using digital twins-based in silico clinical trials in FLAURA2 regimen as front-line treatment of metastatic EGFR-mutated non-small cell lung cancer
Annals of Oncology·2025
Abstract ND06: AMG 305, a dual targeting BiTE®molecule with selective activity for solid tumors that co-express CDH3 and MSLN
Cancer Research·2023· 8 cited
Data from Preclinical Assessment of a MUC12-Targeted BiTE (Bispecific T-cell Engager) Molecule
2023Open Access
Data from Preclinical Assessment of a MUC12-Targeted BiTE (Bispecific T-cell Engager) Molecule
2023Open Access
Supplementary Data from Preclinical Assessment of a MUC12-Targeted BiTE (Bispecific T-cell Engager) Molecule
2023Open Access
Supplementary Data from Preclinical Assessment of a MUC12-Targeted BiTE (Bispecific T-cell Engager) Molecule
2023Open Access
Supplemental Materials and Methods from Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy
2023Open Access
Supplemental Figures 1-5 and Methods from Translational Impact of Nanoparticle–Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer
2023Open Access
Data from Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle–Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer
2023Open Access
Data from Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle–Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer
2023Open Access
Supplemental Figure Legends from Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy
2023Open Access
Supplemental Figures S1-S6 from Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy
2023Open Access
Data from Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy
2023Open Access
Supplemental Tables S1-S3 from Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy
2023Open Access
Supplemental Figures 1-5 and Methods from Translational Impact of Nanoparticle–Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer
2023Open Access
Data from Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy
2023Open Access
Supplemental Figures S1-S6 from Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle–Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer
2023Open Access
Supplemental Figures S1-S6 from Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy
2023Open Access
Supplemental Figure Legends from Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Robert S. Kerbel(16), Shan Man(15), Kevin Truong(13), Scott Eliasof(8), Douglas Lazarus(8), Christian Peters(8), Florence T.H. Wu(8), Christina R. Lee(7), Yuval Shaked(7), Santosh Hariharan(7), Ksenia Magidey(7), Ofrat Beyar‐Katz(7), Valeria Miller(7), Isaac T. S. Li(6), Ping Xu(6), Julie M. Bailis(5), Edward G. Garmey(4), Carolyn Krasner(4), Evan Mills(4), Melissa Yin(4)